Details

Autor(en) / Beteiligte

• Kotova, Elena S
• Savochkina, Yulia A
• Doludin, Yuriy V
• Vasilyev, Alexander O
• Prilepskay, Elena A
• Potoldykova, Natalia V
• Babalyan, Konstantin A
• Kanygina, Alexandra V
• Morozov, Andrey O
• Govorov, Alexander V
• Enikeev, Dmitry V
• Kostryukova, Elena S
• Ilina, Elena N
• Govorun, Vadim M
• Pushkar, Dmitry Y
• Sharova, Elena I

Titel

Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples

Ist Teil von

• Research and reports in urology, 2020-01, Vol.12, p.403-413

Ort / Verlag

England: Taylor & Francis Ltd

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Preclinical evaluation of and transcript simultaneous detection in urine to diagnose clinical significant prostate cancer (prostate cancer with Gleason score ≥7) in a Russian cohort. We analyzed urine samples of patients with a total serum PSA ≥2 ng/mL: 31 men with prostate cancer scheduled for radical prostatectomy, 128 men scheduled for first diagnostic biopsy (prebiopsy cohort). , , and transcripts were detected by multiplex reverse transcription quantitative polymerase chain reaction, and the results were used for scores for calculation and statistical analysis. There was no significant difference between clinically significant and nonsignificant prostate cancer PCA3 scores. However, there was a significant difference in the AMACR score (patients scheduled for radical prostatectomy =0.0088, prebiopsy cohort =0.029). We estimated AUCs, optimal cutoffs, sensitivities and specificities for PCa and csPCa detection in the prebiopsy cohort by tPSA, PCA3 score, PCPT Risk Calculator and classification models based on tPSA, PCA3 score and AMACR score. In the clinically significant prostate cancer ROC analysis, the PCA3 score AUC was 0.632 (95%CI: 0.511-0.752), the AMACR score AUC was 0.711 (95%CI: 0.617-0.806) and AUC of classification model based on the score, the AMACR score and total PSA was 0.72 (95%CI: 0.58-0.83). In addition, the correlation of the AMACR score with the ratio of total RNA and RNA of prostate cells in urine was shown (tau=0.347, =6.542e-09). Significant amounts of nonprostate RNA in urine may be a limitation for the AMACR score use. The AMACR score is a good predictor of clinically significant prostate cancer. Significant amounts of nonprostate RNA in urine may be a limitation for the AMACR score use. Evaluation of the AMACR score and classification models based on it for clinically significant prostate cancer detection with larger samples and a follow-up analysis is promising.